UPDATE: Stifel Nicolaus Initiates Conceptus at Buy on Barrier Removal Outlook
Stifel Nicolaus initiated coverage on Conceptus (NASDAQ: CPTS) with a Buy rating and a $26 price target.
Stifel Nicolaus noted, "We asked doctor contacts about the biggest obstacles to greater Essure adoption. The two most frequently cited answers were insurance/cost and poor compliance with hysterosalpingogram ("HSG") confirmation test. Due to the Affordable Care Act (ACA), insurance/cost issues are in the midst of being removed. The HSG is being addressed via a recently initiated clinical trial and, if successful, will be removed in 2015-2016. In the international business, France's favorable UNCAM insurance reversal should help reinvigorate European growth rates."
Conceptus closed at $22.17 on Wednesday.
Latest Ratings for CPTS
|May 2013||Raymond James||Downgrades||Outperform||Market Perform|
|May 2013||Roth Capital||Downgrades||Buy||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.